PCT patent application filed for Welnx small-molecule platform

Welnx Therapeutics has filed PCT patent application WO/2026/000074, covering its locally delivered small-molecule compositions and their use in chronic inflammatory disease.

The filing protects the company's core approach: small molecules formulated for direct application to inflamed tissue — nasal spray for the sinonasal mucosa, eye drops for the ocular surface — with minimal systemic exposure.

Patent details

Application: PCT WO/2026/000074. Filing date: 25 June 2025.